Ireland
--:--IST
Clinical Trials in the EU / 2026-527244-40-00
Authorised, not yet recruiting Phase I

Open-label, Multi-center, Single-dose Phase 1 Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Milvexian in Pediatric Patients From 28 Days to Less Than 18 Years of Age at Risk of Thromboembolic Events

2026-527244-40-00 · tracked via the Priya Life Science EU tracker
Sponsor type
Pharmaceutical company
Therapeutic area
Cardiovascular Diseases
Decision date
09/11/2026
Enrollment target
5
Sites
Austria

Condition studied

Thromboembolic Events

Investigational medicinal product(s)

JNJ-70033093

Every trial of Milvexian across our registers →

Eligibility

Age group
0-17 years
Sex
Female, Male

Primary endpoint

Plasma milvexian Cmax, tmax, AUC∞, AUClast, and t1/2

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-527244-40-00 on CTIS ↗ ← All trials in the EU